Effects of β-hydroxy-β-methylbutyrate supplementation on muscle mass and strength in onabotulinumtoxin type-A-injected and contralateral quadriceps femoris in rabbits

Authors

  • Rafael Fortuna Human Performance Laboratory, University of Calgary, Calgary, Canada
  • Andrew Sawatsky
  • John C. Fuller, Jr Research, Metabolic Technologies LLC, Missoula, USA
  • Walter Herzog

DOI:

https://doi.org/10.2340/16501977-2866

Keywords:

botulinum toxin, Botox®, β-hydroxy-β-methylbutyrate supplementation, muscle strength, muscle mass, skeletal muscle

Abstract

Objective: To determine the effects of the leucine metabolite β-hydroxy-β-methylbutyrate (HMB) on strength, muscle mass, and contractile material in muscle wasting induced by onabotulinumtoxin type-A (BoNT-A) injection into the quadriceps femoris muscles of New Zealand white rabbits.

Methods: A total of 21, female rabbits were divided into 3 groups (n = 7, each). Group 1 (Control) received intramuscular injection of saline. Groups 2 and 3 received intramuscular injection of BoNT-A (3.5 units/kg), with group 3 receiving supplementation with HMB (120 mg/kg-BW/day). Muscle morphology, mass, and strength were assessed 8 weeks later in both injected and non-injected contralateral limbs.

Results: Injected muscle strength of group 2 (BoNT-A) and group 3 (BoNT-A+HMB) was reduced by 63% and 60%, respectively, compared with Controls (p < 0.0001). Strength in contralateral muscles of group 2 was reduced by 23% vs Controls (p <0.002), while in group 3, strength was similar to Controls. Muscle mass in the injected muscles of the BoNT-A and BoNT-A+HMB groups was significantly reduced, by 46% and 48%, respectively.

Conclusion: While HMB did not prevent loss of muscle strength and mass in the BoNT-A-injected musculature, it prevented significant loss of contractile material in the injected musculature and strength loss in the contralateral non-injected musculature.

Lay Abstract

Onabotulinum toxin A (BoNT-A) is currently approved for cosmetic procedures and for the treatment of many conditions, such as migraine headaches and neuromuscular conditions associated with spasticity, such as cerebral palsy or post-stroke in USA. Once injected into the muscle BoNT-A causes muscle paralysis, which is reversible. The current study examined the local and distant detrimental effects of BoNT-A on decreasing muscle wasting and muscle function in a rabbit model, and the effects of dietary use of HMB (β-hydroxy-β-methylbutyrate), a leucine metabolite, on these detrimental effects. BoNT-A was injected into 1 leg of a rabbit model and muscle mass and strength measured in both the injected and non-injected legs. BoNT-A caused a loss of muscle mass in the injected legs. It also caused a loss of strength in the injected legs and a somewhat reduced loss of strength in the non-injected legs. This suggests that BoNT-A injections can cause a decrease in function in distant, non-target muscles. HMB partially reversed some of the detrimental side-effects of BoNT-A, being shown to be effective in maintaining muscle strength in the non-injected leg.

References

Bales CW, Ritchie CS. Sarcopenia, weight loss, and nutritional frailty in the elderly. Annu Rev Nutr 2002; 22: 309–323.

Baier S, Johannsen D, Abumrad NN, Rathmacher JA, Nissen SL, Flakoll PJ. Year-long changes in lean body mass in elderly men and women supplemented with a nutritional cocktail of β-hydroxy-β-methylbutyrate (HMB), arginine, and lysine. JPEN 2009; 33: 71–82.

Cherniack EP, Florez HJ, Troen BR. Emerging therapies to treat frailty syndrome in the elderly. Altern Med Rev 2007; 12: 246–258.

Deutz NE, Pereira SL, Hays NP, Oliver JS, Edens NK, Evans CM, et al. Effect of beta-hydroxy-beta-methylbutyrate (HMB) on lean body mass during 10 days of bed rest in older adults. Clin Nutr 2013; 32: 704–712.

Wilson JM, Fitschen PJ, Campbell B, Wilson GJ, Zanchi N, Taylor L, et al. International Society of Sports Nutrition Position Stand: beta-hydroxy-beta-methylbutyrate (HMB). J Int Soc Sports Nutr 2013; 10: 6.

Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev 1981; 33: 155–188.

Simpson L. The life history of a botulinum toxin molecule. Toxicon 2013; 68: 40–59.

Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl 1997; 6: S146–S168.

Tighe AP, Schiavo G. Botulinum neurotoxins: mechanism of action. Toxicon 2013; 67: 87–93.

Longino D, Frank C, Leonard TR, Vaz MA, Herzog W. Proposed model of botulinum toxin-induced muscle weakness in the rabbit. J Orthop Res 2005; 23: 1411–1418.

Graham HK. Botulinum toxin type A management of spasticity in the context of orthopaedic surgery for children with spastic cerebral palsy. Eur J Neurol2001; 8: 30–39.

Longino D, Frank C, Herzog W. Acute botulinum toxin-induced muscle weakness in the anterior cruciate ligament-deficient rabbit. J Orthop Res 2005; 23: 1404–1410.

Rosales RL, Chua-Yap AS. Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity. J Neural Transm (Vienna) 2008; 115: 617–623.

Borodic GE, Ferrante R, Pearce LB, Smith K. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. Mov Disord. 1994; 9: 31–39.

Cichon JV, Jr., McCaffrey TV, Litchy WJ, Knops JL. The effect of botulinum toxin type A injection on compound muscle action potential in an in vivo rat model. Laryngoscope 1995; 105: 144–148.

Tsai SW, Tung YT, Chen HL, Shen CJ, Chuang CH, Tang TY, et al. Treadmill running upregulates the expression of acetylcholine receptor in rat gastrocnemius following botulinum toxin A injection. J Orthop Res 2013; 31: 125–131.

Egloff C, Sawatsky A, Leonard T, Hart DA, Valderrabano V, Herzog W. Effect of muscle weakness and joint inflammation on the onset and progression of osteoarthritis in the rabbit knee. Osteoarthritis Cartilage 2014; 22: 1886–1893.

Rehan YA, Longino D, Seerattan R, Leonard T, Herzog W. Muscle weakness causes joint degeneration in rabbits. Osteoarthritis Cartilage 2009; 17: 1228–1235.

Fortuna R, Horisberger M, Vaz MA, Van der MR, Herzog W. The effects of electrical stimulation exercise on muscles injected with botulinum toxin type-A (botox). J Biomech 2013; 46: 36–42.

Nissen SL, Abumrad NN. Nutritional role of the leucine metabolite β-hydroxy-β-methylbutyrate (HMB). J Nutr Biochem 1997; 8: 300–311.

Nissen S, Sharp R, Ray M, Rathmacher JA, Rice D, Fuller JC, Jr., et al. Effect of leucine metabolite β-hydroxy β-methylbutyrate on muscle metabolism during resistance-exercise training. J Appl Physiol 1996; 81: 2095–2104.

Panton LB, Rathmacher JA, Baier S, Nissen S. Nutritional supplementation of the leucine metabolite β-hydroxy β-methylbutyrate (HMB) during resistance training. Nutrition 2000; 16: 734–739.

Vukovich MD, Stubbs NB, Bohlken RM. Body composition in 70-year old adults responds to dietary β-hydroxy-β-methylbutyrate (HMB) similar to that of young adults. J Nutr 2001; 131: 2049–2052.

Wilson JM, Kim JS, Lee SR, Rathmacher JA, Dalmau B, Kingsley JD, et al. Acute and timing effects of beta-hydroxy-beta-methylbutyrate (HMB) on indirect markers of skeletal muscle damage. Nutr Metab (Lond) 2009; 6: 6.

Clark RH, Feleke G, Din M, Yasmin T, Singh G, Khan F, et al. Nutritional treatment for acquired immunodeficiency virus-associated wasting using β-hydroxy-β-methylbutyrate, glutamine and arginine: a randomized, double-blind, placebo-controlled study. JPEN J Parenter Enteral Nutr 2000; 24: 133–139.

Kuhls DA, Rathmacher JA, Musngi MD, Frisch DA, Nielson J, Barber A, et al. Beta-hydroxy-beta-methylbutyrate supplementation in critically ill trauma patients. J Trauma 2007; 62: 125–131.

Eubanks May P, Barber A, Hourihane A, D’Olimpio JT, Abumrad NN. Reversal of cancer-related wasting using oral supplementation with a combination of β-hydroxy-β-methylbutyrate, arginine, and glutamine. Am J Surg 2002; 183: 471–479.

Kovarik M, Muthny T, Sispera L, Holecek M. Effects of beta-hydroxy-beta-methylbutyrate treatment in different types of skeletal muscle of intact and septic rats. J Physiol Biochem 2010; 66: 311–319.

Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008; 22: 659–661.

Herzog W, Leonard TR. Depression of cat soleus-forces following isokinetic shortening. J Biomech 1997; 30: 865–872.

Fortuna R, Vaz MA, Youssef AR, Longino D, Herzog W. Changes in contractile properties of muscles receiving repeat injections of botulinum toxin (Botox). J Biomech 2011; 44: 39–44.

Leumann A, Longino D, Fortuna R, Leonard T, Vaz MA, Hart DA, et al. Altered cell metabolism in tissues of the knee joint in a rabbit model of Botulinum toxin A-induced quadriceps muscle weakness. Scand J Med Sci Sports 2012; 22: 776–782.

Fortuna R, Vaz MA, Sawatsky A, Hart DA, Herzog W. A clinically relevant BTX-A injection protocol leads to persistent weakness, contractile material loss, and an altered mRNA expression phenotype in rabbit quadriceps muscles. J Biomech 2015; 48: 1700–1706.

Simpson LL. Identification of the major steps in botulinum toxin action. Ann Rev Pharmacol Toxicol 2004; 44: 167–193.

Wilkinson DJ, Hossain T, Hill DS, Phillips BE, Crossland H, Williams J, et al. Effects of leucine and its metabolite beta-hydroxy-beta-methylbutyrate on human skeletal muscle protein metabolism. J Physiol 2013; 591: 2911–2923.

Smith HJ, Mukerji P, Tisdale MJ. Attenuation of proteasome-induced proteolysis in skeletal muscle by β-hydroxy-β-methylbutyrate in cancer-induced muscle loss. Cancer Res 2005; 65: 277–283.

Eley HL, Russell ST, Tisdale MJ. Mechanism of attenuation of muscle protein degradation induced by tumor necrosis factor alpha and angiotensin II by beta-hydroxy-beta-methylbutyrate. Am J Physiol Endocrinol Metab 2008; 295: E1417–E1426.

Russell ST, Tisdale MJ. Mechanism of attenuation by beta-hydroxy-beta-methylbutyrate of muscle protein degradation induced by lipopolysaccharide. Mol Cell Biochem 2009; 330: 171–179.

Eley HL, Russell ST, Tisdale MJ. Attenuation of depression of muscle protein synthesis induced by lipopolysaccharide, tumor necrosis factor and angiotensin II by β-hydroxy-β-methylbutyrate. Am J Physiol Endocrinol Metab 2008; 295: E1409–E1416.

Wilkinson DJ, Hossain T, Limb MC, Phillips BE, Lund J, Williams JP, et al. Impact of the calcium form of beta-hydroxy-beta-methylbutyrate upon human skeletal muscle protein metabolism. Clin Nutr 2018; 37: 2068–2075.

Downloads

Published

2021-09-22

How to Cite

Fortuna, R., Sawatsky, A., Fuller, Jr, J. C., & Herzog, W. (2021). Effects of β-hydroxy-β-methylbutyrate supplementation on muscle mass and strength in onabotulinumtoxin type-A-injected and contralateral quadriceps femoris in rabbits. Journal of Rehabilitation Medicine, 53(9 (September), jrm00229. https://doi.org/10.2340/16501977-2866

Issue

Section

Original Report

Categories